Troels Lillebaek
@tlillebaek.bsky.social
Professor infectious Disease | focus molecular epidemiology | Global Health Section | Uni. of Copenhagen. Director | Int. Reference Lab. of Mycobacteriology | Statens Serum Institut | Copenhagen | DK. TB/NTM, Infection, transmission & control | Own views
Pinned
Troels Lillebaek
@tlillebaek.bsky.social
· Nov 29
Troels Lillebæk
researchprofiles.ku.dk
Personal profile on the University of Copenhagen homepage, including a short presentation, primary research fields, research output, and collaborations.
Thanks to all participants for a fantastic meeting with focus on all aspects of #mycobacteriology at #ESMyco2025
And that's a wrap on #ESM2025! A huge thank you to our incredible community of scientists, speakers, and organizers who made this week unforgettable. The future of mycobacteriology is bright! See you all in 2026! 👋 #Tuberculosis #Science
July 3, 2025 at 5:28 AM
Thanks to all participants for a fantastic meeting with focus on all aspects of #mycobacteriology at #ESMyco2025
Reposted by Troels Lillebaek
Great presentation from Xenia at #esm2025 supported by @micronorman.bsky.social and @tlillebaek.bsky.social and others on decades of NTM isolates from patients and how it changes over those years.
June 23, 2025 at 11:13 AM
Great presentation from Xenia at #esm2025 supported by @micronorman.bsky.social and @tlillebaek.bsky.social and others on decades of NTM isolates from patients and how it changes over those years.
Reposted by Troels Lillebaek
A huge congratulations to
@jodyphelan.bsky.social from @lshtm.bsky.social l for receiving the Gertrud Meissner Award at #ESM2025! 🏆 His work on bioinformatic pipelines to predict drug resistance is truly impactful. Well deserved! 🎉 #Tuberculosis #Awards #Science
@jodyphelan.bsky.social from @lshtm.bsky.social l for receiving the Gertrud Meissner Award at #ESM2025! 🏆 His work on bioinformatic pipelines to predict drug resistance is truly impactful. Well deserved! 🎉 #Tuberculosis #Awards #Science
June 22, 2025 at 5:06 PM
A huge congratulations to
@jodyphelan.bsky.social from @lshtm.bsky.social l for receiving the Gertrud Meissner Award at #ESM2025! 🏆 His work on bioinformatic pipelines to predict drug resistance is truly impactful. Well deserved! 🎉 #Tuberculosis #Awards #Science
@jodyphelan.bsky.social from @lshtm.bsky.social l for receiving the Gertrud Meissner Award at #ESM2025! 🏆 His work on bioinformatic pipelines to predict drug resistance is truly impactful. Well deserved! 🎉 #Tuberculosis #Awards #Science
Reposted by Troels Lillebaek
The prestigious Gardner Middlebrook Award is presented to Brigitte Gicquel from @pasteur.fr at #ESM2025. 🏆 Congratulations on this incredible honor, recognizing your immense contributions to our understanding of TB genetics and virulence. 👏 #Mycobacteriology
June 22, 2025 at 5:12 PM
The prestigious Gardner Middlebrook Award is presented to Brigitte Gicquel from @pasteur.fr at #ESM2025. 🏆 Congratulations on this incredible honor, recognizing your immense contributions to our understanding of TB genetics and virulence. 👏 #Mycobacteriology
How to #treat #TB patients with #expanded #resistance to one or more of bedaquiline, linezolid, a third-generation fluoroquinolone, a nitroimidazole (pretomanid or delamanid, and/or clofazimine? Clinical experts elaborates best clinical practices, read on:
pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov/articles/PMC...
Clinical best practices for caring for people with expanded resistance to newer TB drugs
Strains of Mycobacterium tuberculosis with resistance to the new and repurposed drugs included in the all-oral shorter TB regimens recommended by WHO for the treatment of multidrug-resistant/rifampici...
pmc.ncbi.nlm.nih.gov
June 18, 2025 at 8:07 AM
How to #treat #TB patients with #expanded #resistance to one or more of bedaquiline, linezolid, a third-generation fluoroquinolone, a nitroimidazole (pretomanid or delamanid, and/or clofazimine? Clinical experts elaborates best clinical practices, read on:
pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov/articles/PMC...
Join course "Optimising Management of TB and Mycobacterial Infections with Genomic Approaches". For mycobacteriology experts and young clinicians. Ideally, candidate trainees should be involved in implementation of NGS technologies for clinical management of TB & other mycobacterial diseases / NTM
Optimising Management of Tuberculosis and Mycobacterial Infections with Genomic Approaches
www.escmid-foundation.org
May 15, 2025 at 8:39 AM
Join course "Optimising Management of TB and Mycobacterial Infections with Genomic Approaches". For mycobacteriology experts and young clinicians. Ideally, candidate trainees should be involved in implementation of NGS technologies for clinical management of TB & other mycobacterial diseases / NTM
New review study from colleagues, On the way to #tuberculosis #elimination, expanded #contact #tracing including additional subgroups may play a role. Perhaps first, let us make sure contact tracing is performed systematically in already recommended groups/populations? doi.org/10.5588/pha....
TB yields from expanded contact tracing investigations: Ingenta ConnectBACKGROUNDMETHODSRESULTSCONCLUSION
doi.org
May 7, 2025 at 9:51 AM
New review study from colleagues, On the way to #tuberculosis #elimination, expanded #contact #tracing including additional subgroups may play a role. Perhaps first, let us make sure contact tracing is performed systematically in already recommended groups/populations? doi.org/10.5588/pha....
Last chance to submit your abstract Monday. Join us at European Society of Mycobacteriology annual congress in Lisbon, Portugal 🔬 #ESMyco
⏰ Deadline extended! Final call to submit abstracts & travel-grant apps for the 45th ESM Congress (#ESM2025) in Lisbon—now 5 May 2025, 23:59 CET. No more extensions, so polish your mycobacteriology work and share it with the world! 🌍✨
Submit ➜ lnkd.in/e5GYMrgc #Mycobacteriology
Submit ➜ lnkd.in/e5GYMrgc #Mycobacteriology
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
May 3, 2025 at 8:18 AM
Last chance to submit your abstract Monday. Join us at European Society of Mycobacteriology annual congress in Lisbon, Portugal 🔬 #ESMyco
Things can change fast. In UK, after > a decade of declining incidence, TB is once again on the rise. In 2024, 5,480 people fell ill with TB in England, an increase of 13% from 2023, marking the highest rise since 1970 and continuing a worrying trend from 2021.
doi.org
April 7, 2025 at 8:54 AM
Things can change fast. In UK, after > a decade of declining incidence, TB is once again on the rise. In 2024, 5,480 people fell ill with TB in England, an increase of 13% from 2023, marking the highest rise since 1970 and continuing a worrying trend from 2021.
Reposted by Troels Lillebaek
Facts and myths about measles - The Lancet Infectious Diseases www.thelancet.com/journals/lan...
Facts and myths about measles
It seems ironic that Robert F Kennedy Jr, one of the most prominent antivaccine activists,
has been made Secretary of Health and Human Services in the USA while one of the largest
recent measles outbr...
www.thelancet.com
March 28, 2025 at 7:59 AM
Facts and myths about measles - The Lancet Infectious Diseases www.thelancet.com/journals/lan...
Reposted by Troels Lillebaek
It's World Tuberculosis Day,let's unite to stop TB in its tracks! 🚫🦠 Join us at the vibrant 45th Annual Congress of the European Society of Mycobacteriology in Lisbon (22-25 June 2025). Save the date, register today! 🎯 www.esmycobacteriology.eu/event-home #EndTB
March 24, 2025 at 2:13 PM
It's World Tuberculosis Day,let's unite to stop TB in its tracks! 🚫🦠 Join us at the vibrant 45th Annual Congress of the European Society of Mycobacteriology in Lisbon (22-25 June 2025). Save the date, register today! 🎯 www.esmycobacteriology.eu/event-home #EndTB
New nationwide study investigating clinical characteristics and diagnostic practices in patients with pulmonary nontuberculous (NTM) isolates.
Clinical Characteristics and Diagnostic Practices in Nontuberculous Mycobacterial Pulmonary Disease: Insights from Denmark
Clinical characteristics of patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in Denmark are undescribed. This study investigated …
www.sciencedirect.com
March 25, 2025 at 4:37 PM
New nationwide study investigating clinical characteristics and diagnostic practices in patients with pulmonary nontuberculous (NTM) isolates.
Reposted by Troels Lillebaek
Happening a week today! If attending in person, please register ASAP - tickets are going fast!
March 17, 2025 at 9:23 AM
Happening a week today! If attending in person, please register ASAP - tickets are going fast!
Pretomanid is a key anti-TB drug. Current EMA-approved label restricts its use to the BPaL regimen & only MDR/XDR-TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This implies using older regimens. In this Editorial, we call for label expansion:
Urgent request for pretomanid label expansion to align with WHO g...: Ingenta Connect
www.ingentaconnect.com
March 13, 2025 at 9:32 AM
Pretomanid is a key anti-TB drug. Current EMA-approved label restricts its use to the BPaL regimen & only MDR/XDR-TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This implies using older regimens. In this Editorial, we call for label expansion:
As the current President of the European Society of Mycobacteriology (ESM), I am pleased to announce that registration is now open for the 45th Annual Congress of ESM, taking place in Lisbon, Portugal, from June 22-25, 2025.
Current meeting | ESM
www.esmycobacteriology.eu
March 11, 2025 at 10:38 AM
As the current President of the European Society of Mycobacteriology (ESM), I am pleased to announce that registration is now open for the 45th Annual Congress of ESM, taking place in Lisbon, Portugal, from June 22-25, 2025.
High-dose isoniazid (H) treatment for MDRTB? High-dose H reported as unlikely to be effective for most patients using the MDRTB regimen because of the high prevalence of high-level H resistance, read on: Gerussi V et al. Emerg Infect Dis. 2025;31(3):633-636.
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
wwwnc.cdc.gov
March 11, 2025 at 9:54 AM
High-dose isoniazid (H) treatment for MDRTB? High-dose H reported as unlikely to be effective for most patients using the MDRTB regimen because of the high prevalence of high-level H resistance, read on: Gerussi V et al. Emerg Infect Dis. 2025;31(3):633-636.
New interesting article, "in vitro" study exploring the feasibility of beta-lactam/beta-lactamase inhibitor combinations with rifampicin to inhibit the growth of MDRTB. Beta-lactam synergy may provide viable combination therapies to address drug resistance in TB link.springer.com/article/10.1...
Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosis - European Journal of Clinical Microbiology & Infectious Diseases
The significant global impact of tuberculosis (TB) on human health is exacerbated by the increasing prevalence of multi-drug resistant tuberculosis (MDR-TB) and the challenges of novel drug discovery ...
link.springer.com
March 11, 2025 at 9:52 AM
New interesting article, "in vitro" study exploring the feasibility of beta-lactam/beta-lactamase inhibitor combinations with rifampicin to inhibit the growth of MDRTB. Beta-lactam synergy may provide viable combination therapies to address drug resistance in TB link.springer.com/article/10.1...
New nationwide study including all patients with #nontuberculous #mycobacteria (NTM) isolates in #Denmark over 32 years (n=4,123), investigating age, sex and geographical differences in NTM incidence.
Relationship between age, sex, geography and incidence of nontuberculous… | Troels L.
In this new nationwide study including all patients with #nontuberculous #mycobacteria (#NTM) isolates in #Denmark over 32 years (n=4,123), we investigated…
www.linkedin.com
March 11, 2025 at 9:47 AM
New nationwide study including all patients with #nontuberculous #mycobacteria (NTM) isolates in #Denmark over 32 years (n=4,123), investigating age, sex and geographical differences in NTM incidence.
Reposted by Troels Lillebaek
Why increasing rates of tuberculosis in the UK and US should concern everyone. theconversation.com/why-increasi...
Ending TB is possible. We have the tools. The investment case is solid. But with UK cutting overseas investment and the USA halting funds to USAID - political will is lacking.
Ending TB is possible. We have the tools. The investment case is solid. But with UK cutting overseas investment and the USA halting funds to USAID - political will is lacking.
Why increasing rates of tuberculosis in the UK and US should concern everyone
England is at risk of losing its ‘low TB incidence’ status.
theconversation.com
March 10, 2025 at 7:15 PM
Why increasing rates of tuberculosis in the UK and US should concern everyone. theconversation.com/why-increasi...
Ending TB is possible. We have the tools. The investment case is solid. But with UK cutting overseas investment and the USA halting funds to USAID - political will is lacking.
Ending TB is possible. We have the tools. The investment case is solid. But with UK cutting overseas investment and the USA halting funds to USAID - political will is lacking.
Reposted by Troels Lillebaek
Hello @bsky.app 🦋! We’re the European Society of Mycobacteriology (ESM) on a mission to decode the mysteries of mycobacteria 🦠🔬. Stay tuned for exciting research, TB updates, and more. Let’s shape the future of global health together!
January 29, 2025 at 7:39 PM
Hello @bsky.app 🦋! We’re the European Society of Mycobacteriology (ESM) on a mission to decode the mysteries of mycobacteria 🦠🔬. Stay tuned for exciting research, TB updates, and more. Let’s shape the future of global health together!
Sad news, but webinar looks very interesting 🩺
After falling for 10 years, rates of #tuberculosis in the UK are on the rise. 📈
Join the latest free webinar from @ucltb.bsky.social to discuss why this is happening, and how we can best respond.
📆 Thurs 6 February
🕒 3pm - 5pm
📍 Online
Sign up now 👉 https://buff.ly/4agqAxE
Join the latest free webinar from @ucltb.bsky.social to discuss why this is happening, and how we can best respond.
📆 Thurs 6 February
🕒 3pm - 5pm
📍 Online
Sign up now 👉 https://buff.ly/4agqAxE
January 23, 2025 at 7:35 AM
Sad news, but webinar looks very interesting 🩺
Exciting new discovery of four (!) new nontuberculous mycobacterium species M. wendilense, M. burgundiense, M. kokjensenii, and M. holstebronense. Read all the details in this LinkedIn article, which also includes a link to the Danish press release and further reading
Troels L. on LinkedIn: Exciting Discovery: Four New Nontuberculous Mycobacterium Species…
Exciting discovery of four (!) new nontuberculous mycobacterium species Mycobacterium #wendilense, Mycobacterium #burgundiense, Mycobacterium #kokjensenii, and…
www.linkedin.com
January 16, 2025 at 10:45 AM
Exciting new discovery of four (!) new nontuberculous mycobacterium species M. wendilense, M. burgundiense, M. kokjensenii, and M. holstebronense. Read all the details in this LinkedIn article, which also includes a link to the Danish press release and further reading
Jobmulighed for #læge, #hoveduddannelseslæge eller #speciallæge? Ønsker du mere tid til forskning i #tuberkulose / #mykobakterier? Se spændende job i Afdeling for Tuberkulose og Mykobakterier på SSI. Fortsæt med igangværende projekter og afprøv nye ideer. Læs nærmere her:
Læge til Afdeling for Tuberkulose og Mykobakterier
Er du uddannet læge med interesse for tuberkulose og atypiske mykobakterier? Har du forskningserfaring men ønsker mere tid til forskningen? Så er du måske den n
candidate.hr-manager.net
January 15, 2025 at 10:15 AM
Jobmulighed for #læge, #hoveduddannelseslæge eller #speciallæge? Ønsker du mere tid til forskning i #tuberkulose / #mykobakterier? Se spændende job i Afdeling for Tuberkulose og Mykobakterier på SSI. Fortsæt med igangværende projekter og afprøv nye ideer. Læs nærmere her:
Tongue #swabbing for #tuberculosis #diagnosis shows some potential in a new article. However, it's crucial to also remmeber drug susceptibility testing and identifying non-tuberculous mycobacteria (NTM).
Rapid quantitative PCR on tongue swabs for pulmonary tuberculosis in adults: a prospective multicentre study
pmc.ncbi.nlm.nih.gov
January 6, 2025 at 11:47 AM
Tongue #swabbing for #tuberculosis #diagnosis shows some potential in a new article. However, it's crucial to also remmeber drug susceptibility testing and identifying non-tuberculous mycobacteria (NTM).